All In Biotech

Drug Trial Radar · NCT06558656

Effect of Food of NTQ5082 in Healthy Subjects

A Randomized, Open Label, Two Sequence, Two Period, Double Crossover-design Phase I Clinical Trial of NTQ5082 Capsules Taken by Healthy Subjects on an Empty Stomach (i.e, Fasting) as Well as After a Meal (i.e. Fed)

Last checked: Nov 19, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

12

Planned (sponsor's estimate)

Start

Aug 2024

Primary completion

Dec 2024

Study completion Feb 2025

Sponsor

Sponsor type
Industry
First posted
Aug 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, open label, two sequence, two period, double crossover-design phase 1 clinical trial to evaluate the food effect on PK after a single oral administration of NTQ5082 capsules and the safety and tolerability of single oral administration of NTQ5082 capsules on an empty stomach (i.e, fasting) as well as after a meal (i.e. fed) in healthy subjects

Conditions

  • Complement-mediated Hemolytic Diseases

Interventions

  • NTQ5082 capsuleDrug

    Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle. Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-lastTime frame: up to 15 days
  2. AUC0-∞Time frame: up to 15 days
  3. CmaxTime frame: up to 15 days
  4. TmaxTime frame: up to 15 days
  5. t1/2Time frame: up to 15 days
  6. CL/FTime frame: up to 15 days
  7. Vz/FTime frame: up to 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third hospital of Changsha

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.